Key result
EVI antibodies remained positive in 60% (6 of 10) of Nifurtimox-treated Chagas's disease patients despite becoming seronegative for T. cruzi, suggesting self-perpetuation without infection.
Why the study?
Do EVI antibodies persist in pediatric patients with Chagas's disease who have been successfully treated with Nifurtimox?
Observational (n=10)
Do EVI antibodies persist in pediatric patients with Chagas's disease who have been successfully treated with Nifurtimox?
Answers are grounded in this paper and cite their sources.
EVI antibodies may self-perpetuate in the absence of active T. cruzi infection in pediatric patients treated with Nifurtimox.
Antibodies reacting against endothelial cells, vascular structures, and heart and skeletal muscle cells (EVI antibodies) were studied in 10 patients (one to 14 years of age) treated with Nifurtimox. The patients were observed for several months to two years after the onset of symptoms of acute infection with Trypanosoma cruzi. Although these 10 patients were selected because after treatment their sera became negative for antibodies to T. cruzi as detected by the immunofluorescence test, sera from six patients remained positive for EVI antibodies. It is suggested that EVI antibodies may be self-perpetuated in the absence of infection. Further studies are needed to determine the pathogenic significance of EVI antibodies.
No takes yet. Share an insight, caveat, or question.
Schmuñis et al. (1978) conducted an observational in Chagas's disease (acute infection with Trypanosoma cruzi) (n=10). Nifurtimox treatment was evaluated on Presence of EVI antibodies. EVI antibodies remained positive in 60% (6 of 10) of Nifurtimox-treated Chagas's disease patients despite becoming seronegative for T. cruzi, suggesting self-perpetuation without infection.
Synapse has enriched 10 related papers. Consider them for comparative context: